Skip to main
ANNX

Annexon, Inc (ANNX) Stock Forecast & Price Target

Annexon, Inc (ANNX) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 29%
Hold 14%
Sell 14%
Strong Sell 0%

Bulls say

Annexon is a promising biotech company with a strong focus on developing C1q inhibitors for geographic atrophy, a challenging market but with potential for significant sales. The company's current main goal is to achieve vision restoration in GA, with their new drug ANX1502 showing promise in reducing complement activity and having mild side effects. However, profitability may take several years and additional funding, but the company has potential for success with potential for combination treatments and advancements in gene therapy, stem cell therapy, and local delivery of medication to the eye.

Bears say

Annexon is facing potential challenges with its drug candidates, particularly in regards to safety and efficacy concerns. Its financial status and upcoming trials will be crucial in determining the success of its pipeline, but it remains to be seen if these drugs will become market leaders and have a significant impact on the medical community. Given these uncertainties and potential hurdles, a negative outlook is warranted for Annexon's stock.

Annexon, Inc (ANNX) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Annexon, Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Annexon, Inc (ANNX) Forecast

Analysts have given Annexon, Inc (ANNX) a Buy based on their latest research and market trends.

According to 7 analysts, Annexon, Inc (ANNX) has a Buy consensus rating as of Sep 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Annexon, Inc (ANNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.